News
Prevent Blindness offers resources for Cataract Month, empowering patients and caregivers with knowledge on cataracts and ...
A recent US Count of International Trade decision was made on May 28 to permanently prohibit all tariffs imposed by President ...
Telomir-1 shows promising results in restoring vision and retinal structure in age-related macular degeneration, marking a ...
SpyGlass Pharma secures $75 million in Series D funding to enhance its innovative drug delivery platform for long-term ...
Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...
Opus Genetics releases topline results from LYNX-2 evaluating phentolamine ophthalmic solution 0.75%
The phase 3 trial observed the treatment of chronic night driving impairment in keratorefractive patients with reduced ...
The trial will evaluate AXPAXLI in at least 555 patients in a multi-center, double-masked, randomized (2:2:1), 3-arm study.
The drug has been reported previously to cause neuropathy and hypersensitivity reactions in breast cancer patients.
At ARVO 2025, in Salt Lake City, Utah, Emma Lessieru, MD, PhD, talked about her poster on retina extracellular vesicles, and ...
A conversation with David S. Friedman, MD, PhD, on treating uncontrolled open-angle glaucoma in patients with limited options ...
Lori Wright, JD, sat down to talk about a discussion at Collaborative Care Symposium about the risk under federal statutes ...
Sunir Garg, MD, discusses a challenge in ophthalmological procedures: patient discomfort during intravitreal injections ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results